RAPT Therapeutics (RAPT) Net Cash Flow (2020 - 2024)
Historic Net Cash Flow for Therapeutics (RAPT) over the last 5 years, with Q4 2024 value amounting to $131.8 million.
- Therapeutics' Net Cash Flow rose 208035.15% to $131.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $122.3 million, marking a year-over-year increase of 133288.8%. This contributed to the annual value of $122.3 million for FY2024, which is 133288.8% up from last year.
- Per Therapeutics' latest filing, its Net Cash Flow stood at $131.8 million for Q4 2024, which was up 208035.15% from $823000.0 recorded in Q3 2024.
- Over the past 5 years, Therapeutics' Net Cash Flow peaked at $131.8 million during Q4 2024, and registered a low of -$62.6 million during Q2 2020.
- Its 5-year average for Net Cash Flow is $4.6 million, with a median of $2.4 million in 2023.
- As far as peak fluctuations go, Therapeutics' Net Cash Flow tumbled by 86715.72% in 2021, and later surged by 433787.88% in 2022.
- Quarter analysis of 5 years shows Therapeutics' Net Cash Flow stood at $4.7 million in 2020, then plummeted by 867.16% to -$36.0 million in 2021, then skyrocketed by 131.25% to $11.2 million in 2022, then plummeted by 159.23% to -$6.7 million in 2023, then skyrocketed by 2080.35% to $131.8 million in 2024.
- Its Net Cash Flow was $131.8 million in Q4 2024, compared to $823000.0 in Q3 2024 and -$8.2 million in Q2 2024.